Pretreatment With Ruxolitinib Improves Post-Transplant Outcomes in Select Myelofibrosis Patients

A recent study evaluated the impact of pretreatment with the JAK1/2 inhibitor ruxolitinib on outcomes after allogeneic hematopoietic cell transplantation (HSCT) in patients with myelofibrosis. The findings were published in Leukemia.

Researchers included 551 patients into this retrospective analysis: 274 who underwent HSCT without ruxolitinib pretreatment and 277 who underwent HSCT with ruxolitinib pretreatment.

On day 45, the overall leukocyte engraftment was 92%. Engraftment was significantly higher among patients whose disease responded to ruxolitinib, compared with those who had no response or lost response to ruxolitinib (94% vs. 85%; p=0.05).

In terms of post-transplant outcomes, the rate of one-year non-relapse mortality was 22%, without significant difference between the two treatment groups, the authors reported.

While ruxolitinib prior to HSCT did not negatively affect post-transplant outcomes, it was associated with better outcomes among patients with ongoing spleen response at time of transplantation, the authors noted. In a multivariable analysis, ruxolitinib-pretreated patients with ongoing spleen response at the time of HSCT had a significantly lower risk of relapse (8.1% vs. 19.1%; p=0.04), as well as higher rate of two-year event-free survival (68.9% vs. 53.7%; p=0.02).

Kaitlyn D’Onofrio is a digital medical writer. She is interested in musculoskeletal health, the effect of exercise on health, and mental health awareness. When she’s not writing for DocWire, Kaitlyn is teaching yoga classes in her community, promoting wellness to her students.